The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Improvement of drug safety by the use of lipid-based nanocarriers
Open accessAbstract
Drug toxicity is an important factor that contributes significantly to adverse drug events in current healthcare practice. Application of lipid-based nanocarriers in drug formulation is one approach to improve drug safety. Lipid-based delivery systems include micelles, liposomes, solid lipid nanoparticles, nanoemulsions and nanosuspensions. These carriers are generally composed of physiological lipids well tolerated by human body. Delivery of water-insoluble drugs in these formulations increases their solubility and stability in aqueous media and eliminates the need for toxic co-solvents or pH adjustment to solubilize hydrophobic drugs. Association or encapsulation of peptides/proteins within lipid-based carriers protects the labile biologics against enzymatic degradation, hence reducing the therapeutic dose required and risk of dose-dependent toxicity. Most importantly, lipid-based nanocarriers alter the pharmacokinetics and biodistribution of drugs through passive and active targeting, leading to increased drug accumulation at target sites while significantly decreasing non-specific distribution to other tissues. Furthermore, surface modification of these nanocarriers reduces immunogenicity of drug-carrier complexes, imparts stealth by preventing opsonization and removal by phagocytes and minimizes interaction with circulating blood components. In view of heightening attention on drug safety in patient treatment, lipid-based nanocarrier is therefore an important and promising option for formulation of pharmaceutical products to improve treatment safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
A review of stimuli-responsive nanocarriers for drug and gene delivery
Ganta, S., Devalapally, H., Shahiwala, A., & Amiji, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.017 · Cited by 2,155
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Toxicity of Gold Nanoparticles Functionalized with Cationic and Anionic Side Chains
Goodman, C. M., McCusker, C. D., Yilmaz, T., & Rotello, V. M. (2004) · Bioconjugate Chemistry · doi:10.1021/bc049951i · Cited by 1,601
Nanosuspensions in drug delivery
Rabinow, B. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1494 · Cited by 1,524
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,495
Lovell, J. F., Jin, C. S., Huynh, E., Jin, H., Kim, C., Rubinstein, J. L., Chan, W. C. W., Cao, W., Wang, L. V., & Zheng, G. (2011) · Nature Materials · doi:10.1038/nmat2986 · Cited by 1,362
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Ashley, C. E., Carnes, E. C., Phillips, G. K., Padilla, D., Durfee, P. N., Brown, P. A., Hanna, T. N., Liu, J., Phillips, B., Carter, M. B., et al. (2011) · Nature Materials · doi:10.1038/nmat2992 · Cited by 1,024
Pegylation: A Novel Process for Modifying Pharmacokinetics
Harris, J. M., Martin, N. E., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913
Liposomal Drug Delivery Systems: An Update Review
Samad, A., Sultana, Y., & Aqil, M. (2007) · Current Drug Delivery · doi:10.2174/156720107782151269 · Cited by 906
Solid lipid nanoparticles as a drug delivery system for peptides and proteins☆
ALMEIDA, A., & SOUTO, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.007 · Cited by 814
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Role of nanotechnology in targeted drug delivery and imaging: a concise review
Koo, O. M., Rubinstein, I., & Onyuksel, H. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.06.004 · Cited by 718
Dendrimer toxicity: Let's meet the challenge
Jain, K., Kesharwani, P., Gupta, U., & Jain, N. K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.027 · Cited by 710
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Lukyanov, A. N., & Torchilin, V. P. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.004 · Cited by 655
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
(2018) · CRC Press eBooks · doi:10.1201/9780203743577 · Cited by 587
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
“SMART” Drug Delivery Systems: Double-Targeted pH-Responsive Pharmaceutical Nanocarriers
Sawant, R. M., Hurley, J. P., Salmaso, S., Kale, A., Tolcheva, E., Levchenko, T. S., & Torchilin, V. P. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060080h · Cited by 540
Photochemical mechanisms of light-triggered release from nanocarriers
Fomina, N., Sankaranarayanan, J., & Almutairi, A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.02.006 · Cited by 491
Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., & Yang, C. Z. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00007-3 · Cited by 476
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
Moore, T. J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.16.1752 · Cited by 462
The long and short of carbon nanotube toxicity
Kostarelos, K. (2008) · Nature Biotechnology · doi:10.1038/nbt0708-774 · Cited by 436
Lipid nanoparticles for parenteral delivery of actives
Joshi, M. D., & Müller, R. H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.003 · Cited by 433
Active targeting of brain tumors using nanocarriers
Béduneau, A., Saulnier, P., & Benoit, J.-P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.06.011 · Cited by 424
Semple, S. C., Chonn, A., & Cullis, P. R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00128-2 · Cited by 402
Martins, S., Sarmento, B. F. C. C., Ferreira, D., & Souto, E. B. (2007) · PubMed Central · Cited by 399
Manjunath, K., & Venkateswarlu, V. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.006 · Cited by 380
Controlled drug delivery : fundamentals and applications
Robinson, J. R., & Lee, V. H. L. (1987) · Medical Entomology and Zoology · Cited by 349
Novel formulations of taxanes: a review. Old wine in a new bottle?
Hennenfent, K. L., & Govindan, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj100 · Cited by 345
Factors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Macrophage Uptake of Core−Shell Nanoparticles Surface Modified with Poly(ethylene glycol)
Zahr, A. S., Davis, C. A., & Pishko, M. V. (2006) · Langmuir · doi:10.1021/la060951b · Cited by 324
Oral insulin delivery by means of solid lipid nanoparticles.
Sarmento, B. F. C. C., Martins, S., Ferreira, D., & Souto, E. B. (2007) · PubMed Central · Cited by 305
Oyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.002 · Cited by 296
Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model
Gao, J.-Q., Hu, Wang, & Han (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s25853 · Cited by 285
Engineering of nanoemulsions for drug delivery
Sarker, D. (2005) · Current Drug Delivery · doi:10.2174/156720105774370267 · Cited by 268
Ashok, B., Arleth, L., Hjelm, R. P., Rubinstein, I., & Önyüksel, H. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20150 · Cited by 255
Self-citationHamad, I., Hunter, A. C., Szebeni, J., & Moghimi, S. M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.08.276 · Cited by 253
Wong, J., Brugger, A., Khare, A., Chaubal, M., Papadopoulos, P., Rabinow, B., Kipp, J., & Ning, J. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.008 · Cited by 251
Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin
Tang, N., Du, G., Wang, N., Liu, C., Hang, H., & Liang, W. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm027 · Cited by 239
Advances in lipid nanodispersions for parenteral drug delivery and targeting
Constantinides, P. P., Chaubal, M. V., & Shorr, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.013 · Cited by 230
Peters, K. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.77 · Cited by 228
Pegylation: engineering improved pharmaceuticals for enhanced therapy
Molineux, G. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)80004-4 · Cited by 225
Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine
Singh, K. K., & Vingkar, S. K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.035 · Cited by 215
Harivardhan Reddy, L., Sharma, R. K., Chuttani, K., Mishra, A. K., & Murthy, R. S. R. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.02.028 · Cited by 212
MULLER, R. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.07.006 · Cited by 199
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
Gupta, Y., Jain, A., & Jain, S. K. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.7.0004 · Cited by 192
Role of the methoxy group in immune responses to mPEG-protein conjugates
Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200551b · Cited by 185
Pegnology: a review of PEG-ylated systems.
Bhadra, D., Bhadra, S., Jain, P., & Jain, N. K. (2002) · PubMed · Cited by 183
Szebeni, J., Baranyi, L., Savay, S., Bodo, M., Morse, D. S., Basta, M., Stahl, G. L., Bünger, R., & Alving, C. R. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h1319 · Cited by 171
Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages
Yu, S., Lau, Thomas, Jerome, Dickerson, Giorgio, T., Hubbell, & Maron (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s28531 · Cited by 171
Moghimi, S. M., Andersen, A. J., Hashemi, S. H., Lettiero, B., Ahmadvand, D., Hunter, A. C., Andresen, T. L., Hamad, I., & Szebeni, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.003 · Cited by 167
Cationic Liposomes for Gene Delivery: From Biophysics to Biological Applications
de Lima, M. C. P., Neves, S., Filipe, A. D. S., Duzgunes, N., & Simões, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457430 · Cited by 155
Pharmacokinetic Drug Interactions with Phenytoin (Part I)1
Nation, R. L., Evans, A. M., & Milne, R. W. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018010-00003 · Cited by 154
Assessing Iron Oxide Nanoparticle Toxicity In Vitro : Current Status and Future Prospects
Soenen, S. J., & Cuyper, M. D. (2010) · Nanomedicine · doi:10.2217/nnm.10.106 · Cited by 153
Krishnadas, A., Rubinstein, I., & Önyüksel, H. (2003) · Pharmaceutical Research · doi:10.1023/a:1022243709003 · Cited by 152
Self-citationNeuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
Swain, S. M., & Arezzo, J. C. (2008) · PubMed · Cited by 142
Drug delivery to tumours: recent strategies
Reddy, L. H. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.10.0001 · Cited by 141
Exploring the use of novel drug delivery systems for antiretroviral drugs
Ojewole, E. B., Mackraj, I., Naidoo, P., & Govender, T. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.06.020 · Cited by 140
Shmeeda, H., Mak, L., Tzemach, D., Astrahan, P., Tarshish, M., & Gabizon, A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0543 · Cited by 137
Ye, J., Wang, Q., Zhou, X., & Zhang, N. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.10.014 · Cited by 134
Surfactant-induced cell toxicity and cell lysis
Partearroyo, M. A., Ostolaza, H., Goñi, F. M., & Barberá‐Guillem, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90399-6 · Cited by 133
Lim, S., Lee, M., & Kim, C. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.032 · Cited by 128
Self-citationCardiovascular Effects of the Cyclooxygenase Inhibitors
White, W. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000258106.74139.25 · Cited by 128
Cinteză, L. O., Ohulchanskyy, T. Y., Sahoo, Y., Bergey, E. J., Pandey, R. K., & Prasad, P. N. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060015p · Cited by 125
Optimizing efficacy of amphotericin B through nanomodification
Vyas, S. P., & Gupta, S. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.4.417 · Cited by 123
VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies
Dagar, S., Krishnadas, A., Rubinstein, I., Blend, M. J., & Onyüksel, H. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00242-6 · Cited by 119
Lipid based particulate formulations for the delivery of antigen
Copland, M. J., Rades, T., Davies, N. M., & Baird, M. A. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01315.x · Cited by 118
Lipid Carriers: A Versatile Delivery Vehicle for Proteins and Peptides
Rawat, M. S., Singh, D., Saraf, S., & Saraf, S. (2008) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.128.269 · Cited by 116
Tagne, J., Kakumanu, S., & Nicolosi, R. J. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000556 · Cited by 108
Koo, O. M. Y., Rubinstein, I., & Önyüksel, H. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0330-4 · Cited by 106
Self-citationProtein Binding Displacement Interactions and their Clinical Importance
McElnay, J. C., & Pf, D. (1983) · Drugs · doi:10.2165/00003495-198325050-00003 · Cited by 102
A Nanoemulsion Formulation of Tamoxifen Increases Its Efficacy in a Breast Cancer Cell Line
Tagne, J., Kakumanu, S., Ortiz, D., Shea, T. B., & Nicolosi, R. J. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700091j · Cited by 102
Sawant, R. R., Sawant, R. R., & Torchilin, V. P. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.04.016 · Cited by 80
Pires, L. A., Hegg, R., Valduga, C. J., Graziani, S. R., Rodrigues, D. G., & Maranhão, R. C. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0738-2 · Cited by 79
Getting specific: monoclonal antibodies in multiple sclerosis
Lutterotti, A., & Martinꝉ, R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70110-8 · Cited by 77
Current and Future Applications of Immunological Attenuation via Pegylation of Cells and Tissue
Chen, A. M., & Scott, M. D. (2001) · BioDrugs · doi:10.2165/00063030-200115120-00005 · Cited by 74
Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells
Önyüksel, H., Jeon, E., & Rubinstein, I. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.041 · Cited by 71
Self-citationElBayoumi, T. A., & Torchilin, V. P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.01.041 · Cited by 67
Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
González‐Rey, E., Varela, N., Chorny, A., & Delgado, M. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780618966 · Cited by 67
Lipoprotein Nanoplatform for Targeted Delivery of Diagnostic and Therapeutic Agents
Glickson, J. D., Lund‐Katz, S., Zhou, R., Choi, H., Chen, I., Li, H., Corbin, I. R., Popov, A. V., Cao, W., Song, L., et al. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-85998-9_35 · Cited by 65
Inhalable liposomal formulation for vasoactive intestinal peptide
Hajos, F., Stark, B., Hensler, S., Prassl, R., & Mosgoeller, W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.01.046 · Cited by 64
Solid lipid nanoparticles as drug carriers
Heiati, H., TAWASHI, R., & Phillips, N. C. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00236-1 · Cited by 63
Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells
Gupta, Y., Jain, A., Jain, P., & Jain, S. (2007) · Journal of drug targeting · doi:10.1080/10611860701289719 · Cited by 63
Powell, J. S., Nugent, D. J., HARRISON, J. A., Soni, A., Luk, A. Y., STASS, H., & Gorina, E. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02856.x · Cited by 62
Önyüksel, H., MOHANTY, P., & RUBINSTEIN, I. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.08.024 · Cited by 62
Self-citationLee, C., Choi, Y., Huh, E. J., Lee, K., Song, H., Sun, M., Jeong, H., Cho, C., & Bom, H. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.620 · Cited by 58
INTRAVITREAL INJECTION OF LIPOSOME-ENCAPSULATED GANCICLOVIR IN A RABBIT MODEL
Peyman, G. A., Khoobehi, B., Tawakol, M. E., Schulman, J. A., Mortada, H. A., Alkan, H., & Fiscella, R. G. (1987) · Retina · doi:10.1097/00006982-198707040-00005 · Cited by 57
Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer
Cesur, H., Rubinstein, I., Pai, A., & Önyüksel, H. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.09.001 · Cited by 51
Self-citationA novel liposomal formulation of flavopiridol
Yang, X., Zhao, X., Phelps, M. A., Piao, L., Rozewski, D. M., LIU, Q., LEE, L., Marcucci, G., Grever, M. R., Byrd, J. C., et al. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.08.008 · Cited by 50
Ge, W., Li, Y., Li, Z., Zhang, S., Sun, Y., Hu, P., Wang, X., Huang, Y., Si, S., Zhang, X., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0539-9 · Cited by 50
Sahib, M. N., Darwis, Peh, Abdulameer, S. A., & Tan, �. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s25363 · Cited by 49
Nanoparticles in Oncology: The New Theragnostic Molecules
Allegra, A., Penna, G., Alonci, A., Rizzo, V., Russo, S., & Musolino, C. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011796817682 · Cited by 43
Skidan, I. N., Dholakia, P., & Torchilin, V. P. (2008) · Journal of drug targeting · doi:10.1080/10611860802102175 · Cited by 43
Sawant, R. R., Sawant, R., Kale, A. A., & Torchilin, V. P. (2008) · Journal of drug targeting · doi:10.1080/10611860802230240 · Cited by 42
Manojlović, V., Winkler, K., Bunjes, V., Neub, A., Schubert, R., Bugarski, B., & Leneweit, G. (2008) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2008.02.001 · Cited by 37
Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors
Rossi, J., Giasson, S., Khalid, M. N., Delmas, P., Allen, C. J., & Leroux, J. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.03.016 · Cited by 35
Micellar nanomedicine of human neuropeptide Y
Kuzmis, A., Lim, S. B., Desai, E., Jeon, E., Lee, B.-S., Rubinstein, I., & Önyüksel, H. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.01.004 · Cited by 32
Self-citationCardiovascular effects of cyclooxygenase-2 inhibitors
Brophy, J. M. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mog.0b013e3282f026a7 · Cited by 30
Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives
Zhang, J. X., Hansen, C. B., Allen, T. M., Boey, A., & Boch, R. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00442-x · Cited by 30
Nanoparticle Interaction with Plasma Proteins as It Relates to Biodistribution
Treuel, L., & Nienhaus, G. U. (2012) · Frontiers in nanobiomedical research · doi:10.1142/9789813140455_0001 · Cited by 29
Dose and outcome: The hurdle of neutropenia (Review)
Marangolo, M., Bengala, C., Conte, P., Danova, M., Pronzato, P., Rosti, G., & Sagrada, P. (2006) · Oncology Reports · doi:10.3892/or.16.2.233 · Cited by 28
Rubinstein, I., Ikezaki, H., & Önyüksel, H. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.028 · Cited by 15
Self-citationPharmaceutical product withdrawal: Attributions of blame and its impact on trust
Bunniran, S., McCaffrey, D. J., Bentley, J. P., & Bouldin, A. S. (2009) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2008.10.002 · Cited by 13
Evaluation of drug toxicity in clinical trials
Splawinski, J. A., Kuźniar, J., Filipiak, K. J., & Zieliński, W. (2006) · Science and Engineering Ethics · doi:10.1007/s11948-006-0014-y · Cited by 12
Human galanin expresses amphipathic properties that modulate its vasoreactivity in vivo
Dagar, S., Önyüksel, H., Akhter, S. R., et al. (2003) · Peptides · doi:10.1016/j.peptides.2003.08.007 · Cited by 12
Self-citation
Cited by
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems
Duan, Y., Dhar, A., Patel, C., Khimani, M., Neogi, S., Sharma, P., Siva Kumar, N., & Vekariya, R. L. (2020) · RSC Advances · doi:10.1039/d0ra03491f · Cited by 614
Wang, S., Su, R., Nie, S., Sun, M., Zhang, J., Wu, D., & Moustaid-Moussa, N. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.10.002 · Cited by 531
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review
Riaz, M., Riaz, M., Zhang, X., Lin, C., Wong, K., Chen, X., Zhang, G., Lu, A., & Yang, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010195 · Cited by 509
Biodegradable Polymer Nanogels for Drug/Nucleic Acid Delivery
Li, Y., Maciel, D., Rodrigues, J., Shi, X., & Tomás, H. (2015) · Chemical Reviews · doi:10.1021/cr500131f · Cited by 478
Metadata
- Authors
- Lim, S. B., Banerjee, A., & Önyüksel, H.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 163
- Issue
- 1
- Pages
- 34-45
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2011476580
- Cited by
- 324
- References
- 112
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.